Vincent William R, Huiras Paul, Empfield Jennifer, Horbowicz Kevin J, Lewis Keith, McAneny David, Twitchell David
Department of Pharmacy, Boston Medical Center, Boston, MA
Department of Pharmacy, St. Cloud Hospital, St. Cloud, MN.
Am J Health Syst Pharm. 2018 Apr 15;75(8):548-555. doi: 10.2146/ajhp170054. Epub 2018 Feb 21.
Results of an interprofessional formulary initiative to decrease postoperative prescribing of i.v. acetaminophen are reported.
After a medical center added i.v. acetaminophen to its formulary, increased prescribing of the i.v. formulation and a 3-fold price increase resulted in monthly spending of more than $40,000, prompting an organizationwide effort to curtail that cost while maintaining effective pain management. The surgery, anesthesia, and pharmacy departments applied the Institute for Healthcare Improvement's Model for Improvement to implement (1) pharmacist-led enforcement of prescribing restrictions, (2) retrospective evaluation of i.v. acetaminophen's impact on rates of opioid-related adverse effects, (3) restriction of prescribing of the drug to 1 postoperative dose on select patient care services, and (4) guideline-driven pain management according to an enhanced recovery after surgery (ERAS) protocol. Monitored metrics included the monthly i.v. acetaminophen prescribing rate, the proportion of i.v. acetaminophen orders requiring pharmacist intervention to enforce prescribing restrictions, and prescribing rates for select adjunctive analgesics. Within a year of project implementation, the mean monthly i.v. acetaminophen prescribing rate decreased by 83% from baseline to about 6 doses per 100 patient-days, with a decline in the monthly drug cost to about $4,000. Documented pharmacist interventions increased 2.7-fold, and use of oral acetaminophen, ketorolac, and gabapentin in ERAS areas increased by 18% overall.
An interprofessional initiative at a large medical center reduced postoperative use of i.v. acetaminophen by more than 80% and yielded over $400,000 in annual cost savings.
报告一项跨专业处方集计划降低静脉注射对乙酰氨基酚术后处方量的结果。
一家医疗中心将静脉注射对乙酰氨基酚纳入其处方集后,该静脉制剂的处方量增加且价格上涨了3倍,导致每月花费超过40,000美元,促使全机构努力在维持有效疼痛管理的同时削减成本。外科、麻醉科和药房部门应用医疗改进研究所的改进模型来实施:(1)由药剂师主导执行处方限制;(2)回顾性评估静脉注射对乙酰氨基酚对阿片类药物相关不良反应发生率的影响;(3)在特定患者护理服务中将该药物的处方限制为术后一剂;(4)根据术后加速康复(ERAS)方案进行指南驱动的疼痛管理。监测指标包括每月静脉注射对乙酰氨基酚的处方率、需要药剂师干预以执行处方限制的静脉注射对乙酰氨基酚订单比例,以及特定辅助镇痛药的处方率。在项目实施的一年内,静脉注射对乙酰氨基酚的平均每月处方率从基线下降了83%,降至每100患者日约6剂,每月药品成本降至约4,000美元。有记录的药剂师干预增加了2.7倍,ERAS领域口服对乙酰氨基酚、酮咯酸和加巴喷丁的使用总体增加了18%。
一家大型医疗中心的跨专业计划使静脉注射对乙酰氨基酚的术后使用量减少了80%以上,并每年节省成本超过40万美元。